{"product_id":"conduent-pharmaceuticals-life-sciences-operational-transformation","title":"Conduent - Pharmaceuticals \/ Life Sciences Operational Transformation","description":"\u003cp\u003eConduent - Pharmaceuticals \/ Life Sciences Operational Transformation\u003c\/p\u003e\n\n\u003cp\u003eWho is This Vendor Assessment For?\u003c\/p\u003e\n\n\u003cp\u003eNelsonHall’s pharmaceuticals \/ life sciences operational transformation profile on Conduent is a comprehensive assessment of Conduent’s offerings and capabilities, designed for:\u003cbr\u003e\nSourcing managers monitoring the capabilities of existing suppliers of pharmaceuticals \/ life sciences operational transformation services and identifying vendor suitability for operational transformation services RFPs\u003cbr\u003e\nVendor marketing, sales, and business managers looking to benchmark themselves against their peers\u003cbr\u003e\nFinancial analysts and investors specializing in the pharmaceuticals \/ life sciences services sector.\u003c\/p\u003e\n\n\u003cp\u003eKey Findings \u0026amp; Highlights\u003c\/p\u003e\n\n\u003cp\u003eConduent, which was spun off from Xerox Business Services in 2017, has solutions targeting payer, provider, pharma \u0026amp; life sciences, and government health services. Within its pharma and life sciences business, Conduent currently offers:\u003cbr\u003e\nPatient access solutions\u003cbr\u003e\nPatient and provider engagement solutions\u003cbr\u003e\nMedical information and clinical trial support.\u003c\/p\u003e\n\n\u003cp\u003eIn 2020, Conduent began to re-invest in the pharma \u0026amp; life sciences business. As a result of these investments, Conduent grew the pharmaceutical and life sciences pipeline seven times vs. 2019.\u003c\/p\u003e\n\n\u003cp\u003eScope of the Report\u003c\/p\u003e\n\n\u003cp\u003eThe report provides a comprehensive and objective analysis of Conduent’s pharmaceuticals \/ life sciences operational transformation offerings and capabilities, and market and financial strengths, including:\u003cbr\u003e\nIdentification of the company’s strategy, emphasis, and new developments\u003cbr\u003e\nAnalysis of the company’s strengths, weaknesses, and outlook\u003cbr\u003e\nRevenue estimates\u003cbr\u003e\nAnalysis of the profile of the company’s customer base, including the company’s targeting strategy and examples of current contracts\u003cbr\u003e\nAnalysis of the company’s offerings and key service components\u003cbr\u003e\nAnalysis of the company’s delivery organization, including the location of delivery locations.\u003c\/p\u003e","brand":"Technology \u0026 Media","offers":[{"title":"October, 2021 \/ 12 Pages \/ MCW16284890","offer_id":47714854961458,"sku":null,"price":2160.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/conduent-pharmaceuticals-life-sciences-operational-transformation","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}